Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires

Conclusions: Significant improvement was apparent when zoledronic acid was co administered in any treatment in patients with lung cancer. Sleep quality, fatigue and pain parameters also improved, with no positive impact on the symptoms of dyspnea.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Ioannis Tremmas, George Petsatodis, Michael Potoupnis, Stella Laskou, Dimitrios Giannakidis, Stylianos Mantalovas, Charilaos Koulouris, Athanasios Katsaounis, Efstathios Pavlidis, Aikaterini Amaniti, Haidong Huang, Chong Bai, Dongchen Shi, Athanasios Dard Tags: Research Paper Source Type: research